Embecta Corp. (EMBCV) Stock Competitors & Peer Comparison
See (EMBCV) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| EMBCV | $33.33 | -9.33% | 1.9B | N/A | N/A | N/A |
| TAK | $15.44 | +1.68% | 47.5B | 39.58 | $0.38 | +4.14% |
| HLN | $8.93 | +2.59% | 38.7B | 17.43 | $0.50 | +2.22% |
| TEVA | $33.88 | +2.42% | 38.2B | 24.50 | $1.34 | N/A |
| VTRS | $15.67 | -0.16% | 18.1B | -51.87 | -$0.30 | +3.09% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $25.59 | +8.29% | 12.3B | -49.16 | -$0.50 | N/A |
| RGC | $23.43 | +1.21% | 11.7B | -2375.00 | -$0.01 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| RDY | $13.24 | +1.57% | 10.8B | 24.12 | $0.54 | +0.70% |
Stock Comparison
EMBCV vs TAK Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, TAK has a market cap of 47.5B. Regarding current trading prices, EMBCV is priced at $33.33, while TAK trades at $15.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas TAK's P/E ratio is 39.58. In terms of profitability, EMBCV's ROE is -0.23%, compared to TAK's ROE of +0.03%. Regarding short-term risk, EMBCV is more volatile compared to TAK. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check TAK's competition here
EMBCV vs HLN Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, HLN has a market cap of 38.7B. Regarding current trading prices, EMBCV is priced at $33.33, while HLN trades at $8.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas HLN's P/E ratio is 17.43. In terms of profitability, EMBCV's ROE is -0.23%, compared to HLN's ROE of +0.17%. Regarding short-term risk, EMBCV is more volatile compared to HLN. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check HLN's competition here
EMBCV vs TEVA Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, TEVA has a market cap of 38.2B. Regarding current trading prices, EMBCV is priced at $33.33, while TEVA trades at $33.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas TEVA's P/E ratio is 24.50. In terms of profitability, EMBCV's ROE is -0.23%, compared to TEVA's ROE of +0.21%. Regarding short-term risk, EMBCV is more volatile compared to TEVA. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check TEVA's competition here
EMBCV vs VTRS Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, VTRS has a market cap of 18.1B. Regarding current trading prices, EMBCV is priced at $33.33, while VTRS trades at $15.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas VTRS's P/E ratio is -51.87. In terms of profitability, EMBCV's ROE is -0.23%, compared to VTRS's ROE of -0.02%. Regarding short-term risk, EMBCV is more volatile compared to VTRS. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check VTRS's competition here
EMBCV vs ITCI Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, EMBCV is priced at $33.33, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas ITCI's P/E ratio is -180.64. In terms of profitability, EMBCV's ROE is -0.23%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, EMBCV is more volatile compared to ITCI. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check ITCI's competition here
EMBCV vs ELAN Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, ELAN has a market cap of 12.3B. Regarding current trading prices, EMBCV is priced at $33.33, while ELAN trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas ELAN's P/E ratio is -49.16. In terms of profitability, EMBCV's ROE is -0.23%, compared to ELAN's ROE of -0.04%. Regarding short-term risk, EMBCV is more volatile compared to ELAN. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check ELAN's competition here
EMBCV vs RGC Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, RGC has a market cap of 11.7B. Regarding current trading prices, EMBCV is priced at $33.33, while RGC trades at $23.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas RGC's P/E ratio is -2375.00. In terms of profitability, EMBCV's ROE is -0.23%, compared to RGC's ROE of -2.32%. Regarding short-term risk, EMBCV is more volatile compared to RGC. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check RGC's competition here
EMBCV vs CTLT Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, EMBCV is priced at $33.33, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas CTLT's P/E ratio is -27.84. In terms of profitability, EMBCV's ROE is -0.23%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, EMBCV is more volatile compared to CTLT. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check CTLT's competition here
EMBCV vs RDY Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, RDY has a market cap of 10.8B. Regarding current trading prices, EMBCV is priced at $33.33, while RDY trades at $13.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas RDY's P/E ratio is 24.12. In terms of profitability, EMBCV's ROE is -0.23%, compared to RDY's ROE of +0.12%. Regarding short-term risk, EMBCV is more volatile compared to RDY. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check RDY's competition here
EMBCV vs LNTH Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, LNTH has a market cap of 6.5B. Regarding current trading prices, EMBCV is priced at $33.33, while LNTH trades at $102.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas LNTH's P/E ratio is 23.93. In terms of profitability, EMBCV's ROE is -0.23%, compared to LNTH's ROE of +0.24%. Regarding short-term risk, EMBCV is more volatile compared to LNTH. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check LNTH's competition here
EMBCV vs INDV Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, INDV has a market cap of 4.4B. Regarding current trading prices, EMBCV is priced at $33.33, while INDV trades at $37.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas INDV's P/E ratio is 18.17. In terms of profitability, EMBCV's ROE is -0.23%, compared to INDV's ROE of -1.42%. Regarding short-term risk, EMBCV is more volatile compared to INDV. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check INDV's competition here
EMBCV vs AMRX Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, AMRX has a market cap of 4.1B. Regarding current trading prices, EMBCV is priced at $33.33, while AMRX trades at $13.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas AMRX's P/E ratio is 34.80. In terms of profitability, EMBCV's ROE is -0.23%, compared to AMRX's ROE of -1.45%. Regarding short-term risk, EMBCV is more volatile compared to AMRX. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check AMRX's competition here
EMBCV vs SUPN Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, SUPN has a market cap of 2.6B. Regarding current trading prices, EMBCV is priced at $33.33, while SUPN trades at $45.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas SUPN's P/E ratio is -86.34. In terms of profitability, EMBCV's ROE is -0.23%, compared to SUPN's ROE of -0.03%. Regarding short-term risk, EMBCV is more volatile compared to SUPN. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check SUPN's competition here
EMBCV vs DCPH Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, EMBCV is priced at $33.33, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas DCPH's P/E ratio is -11.58. In terms of profitability, EMBCV's ROE is -0.23%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, EMBCV is more volatile compared to DCPH. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check DCPH's competition here
EMBCV vs AVDL Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, EMBCV is priced at $33.33, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, EMBCV's ROE is -0.23%, compared to AVDL's ROE of -0.00%. Regarding short-term risk, EMBCV is more volatile compared to AVDL. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check AVDL's competition here
EMBCV vs HCM Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, HCM has a market cap of 2B. Regarding current trading prices, EMBCV is priced at $33.33, while HCM trades at $11.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas HCM's P/E ratio is 4.27. In terms of profitability, EMBCV's ROE is -0.23%, compared to HCM's ROE of +0.41%. Regarding short-term risk, EMBCV is more volatile compared to HCM. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check HCM's competition here
EMBCV vs BHC Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, BHC has a market cap of 1.8B. Regarding current trading prices, EMBCV is priced at $33.33, while BHC trades at $5.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas BHC's P/E ratio is -1.53. In terms of profitability, EMBCV's ROE is -0.23%, compared to BHC's ROE of +1.21%. Regarding short-term risk, EMBCV is more volatile compared to BHC. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check BHC's competition here
EMBCV vs DVAX Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, EMBCV is priced at $33.33, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas DVAX's P/E ratio is -41.89. In terms of profitability, EMBCV's ROE is -0.23%, compared to DVAX's ROE of -0.08%. Regarding short-term risk, EMBCV is more volatile compared to DVAX. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check DVAX's competition here
EMBCV vs ANIP Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, EMBCV is priced at $33.33, while ANIP trades at $78.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas ANIP's P/E ratio is 19.24. In terms of profitability, EMBCV's ROE is -0.23%, compared to ANIP's ROE of +0.17%. Regarding short-term risk, EMBCV is more volatile compared to ANIP. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check ANIP's competition here
EMBCV vs TARO Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, EMBCV is priced at $33.33, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas TARO's P/E ratio is 30.05. In terms of profitability, EMBCV's ROE is -0.23%, compared to TARO's ROE of +0.03%. Regarding short-term risk, EMBCV is more volatile compared to TARO. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check TARO's competition here
EMBCV vs PRGO Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, PRGO has a market cap of 1.4B. Regarding current trading prices, EMBCV is priced at $33.33, while PRGO trades at $10.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas PRGO's P/E ratio is -0.81. In terms of profitability, EMBCV's ROE is -0.23%, compared to PRGO's ROE of -0.51%. Regarding short-term risk, EMBCV is more volatile compared to PRGO. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check PRGO's competition here
EMBCV vs PAHC Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, PAHC has a market cap of 1.3B. Regarding current trading prices, EMBCV is priced at $33.33, while PAHC trades at $33.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas PAHC's P/E ratio is 13.64. In terms of profitability, EMBCV's ROE is -0.23%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, EMBCV is more volatile compared to PAHC. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check PAHC's competition here
EMBCV vs HROW Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, HROW has a market cap of 1.2B. Regarding current trading prices, EMBCV is priced at $33.33, while HROW trades at $34.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas HROW's P/E ratio is -87.68. In terms of profitability, EMBCV's ROE is -0.23%, compared to HROW's ROE of -0.34%. Regarding short-term risk, EMBCV is more volatile compared to HROW. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check HROW's competition here
EMBCV vs EVO Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, EVO has a market cap of 1B. Regarding current trading prices, EMBCV is priced at $33.33, while EVO trades at $2.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas EVO's P/E ratio is -4.59. In terms of profitability, EMBCV's ROE is -0.23%, compared to EVO's ROE of -0.24%. Regarding short-term risk, EMBCV is more volatile compared to EVO. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check EVO's competition here
EMBCV vs CRON Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, CRON has a market cap of 1B. Regarding current trading prices, EMBCV is priced at $33.33, while CRON trades at $2.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas CRON's P/E ratio is -135.50. In terms of profitability, EMBCV's ROE is -0.23%, compared to CRON's ROE of -0.00%. Regarding short-term risk, EMBCV is more volatile compared to CRON. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check CRON's competition here
EMBCV vs COLL Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, COLL has a market cap of 1B. Regarding current trading prices, EMBCV is priced at $33.33, while COLL trades at $31.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas COLL's P/E ratio is 15.08. In terms of profitability, EMBCV's ROE is -0.23%, compared to COLL's ROE of +0.27%. Regarding short-term risk, EMBCV is more volatile compared to COLL. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check COLL's competition here
EMBCV vs ALVO Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, ALVO has a market cap of 979.8M. Regarding current trading prices, EMBCV is priced at $33.33, while ALVO trades at $3.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas ALVO's P/E ratio is 31.40. In terms of profitability, EMBCV's ROE is -0.23%, compared to ALVO's ROE of +0.35%. Regarding short-term risk, EMBCV is more volatile compared to ALVO. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check ALVO's competition here
EMBCV vs PETQ Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, EMBCV is priced at $33.33, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas PETQ's P/E ratio is 83.73. In terms of profitability, EMBCV's ROE is -0.23%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, EMBCV is more volatile compared to PETQ. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check PETQ's competition here
EMBCV vs PCRX Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, PCRX has a market cap of 878M. Regarding current trading prices, EMBCV is priced at $33.33, while PCRX trades at $22.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas PCRX's P/E ratio is 171.69. In terms of profitability, EMBCV's ROE is -0.23%, compared to PCRX's ROE of +0.01%. Regarding short-term risk, EMBCV is more volatile compared to PCRX. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check PCRX's competition here
EMBCV vs AMPH Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, AMPH has a market cap of 799M. Regarding current trading prices, EMBCV is priced at $33.33, while AMPH trades at $18.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas AMPH's P/E ratio is 10.92. In terms of profitability, EMBCV's ROE is -0.23%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, EMBCV is more volatile compared to AMPH. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check AMPH's competition here
EMBCV vs TLRY Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, TLRY has a market cap of 611.2M. Regarding current trading prices, EMBCV is priced at $33.33, while TLRY trades at $5.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas TLRY's P/E ratio is -0.35. In terms of profitability, EMBCV's ROE is -0.23%, compared to TLRY's ROE of -0.93%. Regarding short-term risk, EMBCV is more volatile compared to TLRY. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check TLRY's competition here
EMBCV vs BDSI Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, EMBCV is priced at $33.33, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas BDSI's P/E ratio is 6.82. In terms of profitability, EMBCV's ROE is -0.23%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, EMBCV is more volatile compared to BDSI. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check BDSI's competition here
EMBCV vs IRWD Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, IRWD has a market cap of 533.3M. Regarding current trading prices, EMBCV is priced at $33.33, while IRWD trades at $3.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas IRWD's P/E ratio is 5.23. In terms of profitability, EMBCV's ROE is -0.23%, compared to IRWD's ROE of -0.39%. Regarding short-term risk, EMBCV is more volatile compared to IRWD. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check IRWD's competition here
EMBCV vs CGC Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, CGC has a market cap of 442.9M. Regarding current trading prices, EMBCV is priced at $33.33, while CGC trades at $1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas CGC's P/E ratio is -0.77. In terms of profitability, EMBCV's ROE is -0.23%, compared to CGC's ROE of -0.51%. Regarding short-term risk, EMBCV is more volatile compared to CGC. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check CGC's competition here
EMBCV vs KMDA Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, KMDA has a market cap of 426.3M. Regarding current trading prices, EMBCV is priced at $33.33, while KMDA trades at $7.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas KMDA's P/E ratio is 21.11. In terms of profitability, EMBCV's ROE is -0.23%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, EMBCV is more volatile compared to KMDA. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check KMDA's competition here
EMBCV vs AQST Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, AQST has a market cap of 400.2M. Regarding current trading prices, EMBCV is priced at $33.33, while AQST trades at $4.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas AQST's P/E ratio is -6.61. In terms of profitability, EMBCV's ROE is -0.23%, compared to AQST's ROE of +1.91%. Regarding short-term risk, EMBCV is more volatile compared to AQST. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check AQST's competition here
EMBCV vs EOLS Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, EOLS has a market cap of 397.1M. Regarding current trading prices, EMBCV is priced at $33.33, while EOLS trades at $6.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas EOLS's P/E ratio is -9.14. In terms of profitability, EMBCV's ROE is -0.23%, compared to EOLS's ROE of +1.75%. Regarding short-term risk, EMBCV is more volatile compared to EOLS. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check EOLS's competition here
EMBCV vs SNDL Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, SNDL has a market cap of 365.5M. Regarding current trading prices, EMBCV is priced at $33.33, while SNDL trades at $1.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas SNDL's P/E ratio is -47.00. In terms of profitability, EMBCV's ROE is -0.23%, compared to SNDL's ROE of -0.01%. Regarding short-term risk, EMBCV is more volatile compared to SNDL. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check SNDL's competition here
EMBCV vs SIGA Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, SIGA has a market cap of 307.7M. Regarding current trading prices, EMBCV is priced at $33.33, while SIGA trades at $4.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas SIGA's P/E ratio is 15.32. In terms of profitability, EMBCV's ROE is -0.23%, compared to SIGA's ROE of +0.11%. Regarding short-term risk, EMBCV is more volatile compared to SIGA. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check SIGA's competition here
EMBCV vs ALIM Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, EMBCV is priced at $33.33, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas ALIM's P/E ratio is 5.28. In terms of profitability, EMBCV's ROE is -0.23%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, EMBCV is more volatile compared to ALIM. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check ALIM's competition here
EMBCV vs ORGO Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, ORGO has a market cap of 299.8M. Regarding current trading prices, EMBCV is priced at $33.33, while ORGO trades at $2.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas ORGO's P/E ratio is -19.42. In terms of profitability, EMBCV's ROE is -0.23%, compared to ORGO's ROE of -0.00%. Regarding short-term risk, EMBCV is more volatile compared to ORGO. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check ORGO's competition here
EMBCV vs TKNO Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, TKNO has a market cap of 275M. Regarding current trading prices, EMBCV is priced at $33.33, while TKNO trades at $5.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas TKNO's P/E ratio is -16.55. In terms of profitability, EMBCV's ROE is -0.23%, compared to TKNO's ROE of -0.24%. Regarding short-term risk, EMBCV is less volatile compared to TKNO. This indicates potentially lower risk in terms of short-term price fluctuations for EMBCV.Check TKNO's competition here
EMBCV vs LNDC Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, EMBCV is priced at $33.33, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas LNDC's P/E ratio is -4.04. In terms of profitability, EMBCV's ROE is -0.23%, compared to LNDC's ROE of -9.05%. Regarding short-term risk, EMBCV is more volatile compared to LNDC. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check LNDC's competition here
EMBCV vs TYHT Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, EMBCV is priced at $33.33, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas TYHT's P/E ratio is -1.61. In terms of profitability, EMBCV's ROE is -0.23%, compared to TYHT's ROE of -0.65%. Regarding short-term risk, EMBCV is more volatile compared to TYHT. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check TYHT's competition here
EMBCV vs LFCR Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, LFCR has a market cap of 212.7M. Regarding current trading prices, EMBCV is priced at $33.33, while LFCR trades at $5.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas LFCR's P/E ratio is -4.46. In terms of profitability, EMBCV's ROE is -0.23%, compared to LFCR's ROE of -1.76%. Regarding short-term risk, EMBCV is more volatile compared to LFCR. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check LFCR's competition here
EMBCV vs EMBC Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, EMBC has a market cap of 197M. Regarding current trading prices, EMBCV is priced at $33.33, while EMBC trades at $3.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas EMBC's P/E ratio is 1.76. In terms of profitability, EMBCV's ROE is -0.23%, compared to EMBC's ROE of -0.17%. Regarding short-term risk, EMBCV is more volatile compared to EMBC. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check EMBC's competition here
EMBCV vs ACB Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, ACB has a market cap of 193.9M. Regarding current trading prices, EMBCV is priced at $33.33, while ACB trades at $3.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas ACB's P/E ratio is -3.17. In terms of profitability, EMBCV's ROE is -0.23%, compared to ACB's ROE of -0.08%. Regarding short-term risk, EMBCV is more volatile compared to ACB. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check ACB's competition here
EMBCV vs REPH Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, EMBCV is priced at $33.33, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas REPH's P/E ratio is -8.04. In terms of profitability, EMBCV's ROE is -0.23%, compared to REPH's ROE of -0.22%. Regarding short-term risk, EMBCV is more volatile compared to REPH. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check REPH's competition here
EMBCV vs DERM Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, DERM has a market cap of 166.8M. Regarding current trading prices, EMBCV is priced at $33.33, while DERM trades at $6.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas DERM's P/E ratio is -16.38. In terms of profitability, EMBCV's ROE is -0.23%, compared to DERM's ROE of -0.36%. Regarding short-term risk, EMBCV is more volatile compared to DERM. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check DERM's competition here
EMBCV vs THTX Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, EMBCV is priced at $33.33, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas THTX's P/E ratio is -17.84. In terms of profitability, EMBCV's ROE is -0.23%, compared to THTX's ROE of +0.47%. Regarding short-term risk, EMBCV is more volatile compared to THTX. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check THTX's competition here
EMBCV vs ASRT Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, ASRT has a market cap of 151.7M. Regarding current trading prices, EMBCV is priced at $33.33, while ASRT trades at $23.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas ASRT's P/E ratio is -4.23. In terms of profitability, EMBCV's ROE is -0.23%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, EMBCV is more volatile compared to ASRT. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check ASRT's competition here
EMBCV vs OGI Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, OGI has a market cap of 149.2M. Regarding current trading prices, EMBCV is priced at $33.33, while OGI trades at $1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas OGI's P/E ratio is -6.62. In terms of profitability, EMBCV's ROE is -0.23%, compared to OGI's ROE of -0.07%. Regarding short-term risk, EMBCV is more volatile compared to OGI. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check OGI's competition here
EMBCV vs CRDL Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, CRDL has a market cap of 125.3M. Regarding current trading prices, EMBCV is priced at $33.33, while CRDL trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas CRDL's P/E ratio is -4.00. In terms of profitability, EMBCV's ROE is -0.23%, compared to CRDL's ROE of -2.29%. Regarding short-term risk, EMBCV is more volatile compared to CRDL. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check CRDL's competition here
EMBCV vs SCTL Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, EMBCV is priced at $33.33, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas SCTL's P/E ratio is -7.86. In terms of profitability, EMBCV's ROE is -0.23%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, EMBCV is more volatile compared to SCTL. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check SCTL's competition here
EMBCV vs PROC Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, EMBCV is priced at $33.33, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas PROC's P/E ratio is 1.53. In terms of profitability, EMBCV's ROE is -0.23%, compared to PROC's ROE of -2.22%. Regarding short-term risk, EMBCV is more volatile compared to PROC. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check PROC's competition here
EMBCV vs OPTN Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, EMBCV is priced at $33.33, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas OPTN's P/E ratio is -4.42. In terms of profitability, EMBCV's ROE is -0.23%, compared to OPTN's ROE of +0.45%. Regarding short-term risk, EMBCV is more volatile compared to OPTN. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check OPTN's competition here
EMBCV vs ZOM Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, EMBCV is priced at $33.33, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas ZOM's P/E ratio is -1.62. In terms of profitability, EMBCV's ROE is -0.23%, compared to ZOM's ROE of -0.19%. Regarding short-term risk, EMBCV is more volatile compared to ZOM. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check ZOM's competition here
EMBCV vs GRVI Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, EMBCV is priced at $33.33, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas GRVI's P/E ratio is 26.05. In terms of profitability, EMBCV's ROE is -0.23%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, EMBCV is more volatile compared to GRVI. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check GRVI's competition here
EMBCV vs CPIX Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, CPIX has a market cap of 84.1M. Regarding current trading prices, EMBCV is priced at $33.33, while CPIX trades at $5.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas CPIX's P/E ratio is -11.45. In terms of profitability, EMBCV's ROE is -0.23%, compared to CPIX's ROE of -0.29%. Regarding short-term risk, EMBCV is more volatile compared to CPIX. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check CPIX's competition here
EMBCV vs ZYNE Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, EMBCV is priced at $33.33, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, EMBCV's ROE is -0.23%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, EMBCV is more volatile compared to ZYNE. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check ZYNE's competition here
EMBCV vs SSIC Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, EMBCV is priced at $33.33, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas SSIC's P/E ratio is 11.93. In terms of profitability, EMBCV's ROE is -0.23%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, EMBCV is more volatile compared to SSIC. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check SSIC's competition here
EMBCV vs ALVOW Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, ALVOW has a market cap of 62.1M. Regarding current trading prices, EMBCV is priced at $33.33, while ALVOW trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas ALVOW's P/E ratio is N/A. In terms of profitability, EMBCV's ROE is -0.23%, compared to ALVOW's ROE of +0.35%. Regarding short-term risk, EMBCV is less volatile compared to ALVOW. This indicates potentially lower risk in terms of short-term price fluctuations for EMBCV.Check ALVOW's competition here
EMBCV vs VLNS Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, EMBCV is priced at $33.33, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas VLNS's P/E ratio is -1.03. In terms of profitability, EMBCV's ROE is -0.23%, compared to VLNS's ROE of N/A. Regarding short-term risk, EMBCV is more volatile compared to VLNS. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check VLNS's competition here
EMBCV vs DRRX Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, EMBCV is priced at $33.33, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas DRRX's P/E ratio is -4.44. In terms of profitability, EMBCV's ROE is -0.23%, compared to DRRX's ROE of +0.13%. Regarding short-term risk, EMBCV is more volatile compared to DRRX. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check DRRX's competition here
EMBCV vs BGM Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, BGM has a market cap of 58.2M. Regarding current trading prices, EMBCV is priced at $33.33, while BGM trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas BGM's P/E ratio is -1.00. In terms of profitability, EMBCV's ROE is -0.23%, compared to BGM's ROE of -0.03%. Regarding short-term risk, EMBCV is less volatile compared to BGM. This indicates potentially lower risk in terms of short-term price fluctuations for EMBCV.Check BGM's competition here
EMBCV vs INCR Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, INCR has a market cap of 56.9M. Regarding current trading prices, EMBCV is priced at $33.33, while INCR trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas INCR's P/E ratio is -4.52. In terms of profitability, EMBCV's ROE is -0.23%, compared to INCR's ROE of -0.09%. Regarding short-term risk, EMBCV is more volatile compared to INCR. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check INCR's competition here
EMBCV vs JUPW Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, EMBCV is priced at $33.33, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas JUPW's P/E ratio is -2.41. In terms of profitability, EMBCV's ROE is -0.23%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, EMBCV is less volatile compared to JUPW. This indicates potentially lower risk in terms of short-term price fluctuations for EMBCV.Check JUPW's competition here
EMBCV vs QLI Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, EMBCV is priced at $33.33, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas QLI's P/E ratio is -4.92. In terms of profitability, EMBCV's ROE is -0.23%, compared to QLI's ROE of -0.16%. Regarding short-term risk, EMBCV is more volatile compared to QLI. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check QLI's competition here
EMBCV vs ZYBT Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, ZYBT has a market cap of 37.7M. Regarding current trading prices, EMBCV is priced at $33.33, while ZYBT trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas ZYBT's P/E ratio is -3.61. In terms of profitability, EMBCV's ROE is -0.23%, compared to ZYBT's ROE of -0.26%. Regarding short-term risk, EMBCV is more volatile compared to ZYBT. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check ZYBT's competition here
EMBCV vs IXHL Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, IXHL has a market cap of 35.1M. Regarding current trading prices, EMBCV is priced at $33.33, while IXHL trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas IXHL's P/E ratio is -0.18. In terms of profitability, EMBCV's ROE is -0.23%, compared to IXHL's ROE of -1.23%. Regarding short-term risk, EMBCV is more volatile compared to IXHL. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check IXHL's competition here
EMBCV vs HEXO Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, EMBCV is priced at $33.33, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas HEXO's P/E ratio is -0.26. In terms of profitability, EMBCV's ROE is -0.23%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, EMBCV is more volatile compared to HEXO. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check HEXO's competition here
EMBCV vs SCYX Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, SCYX has a market cap of 29.4M. Regarding current trading prices, EMBCV is priced at $33.33, while SCYX trades at $4.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas SCYX's P/E ratio is -1.22. In terms of profitability, EMBCV's ROE is -0.23%, compared to SCYX's ROE of -0.57%. Regarding short-term risk, EMBCV is more volatile compared to SCYX. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check SCYX's competition here
EMBCV vs RMTI Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, RMTI has a market cap of 26.7M. Regarding current trading prices, EMBCV is priced at $33.33, while RMTI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas RMTI's P/E ratio is -4.50. In terms of profitability, EMBCV's ROE is -0.23%, compared to RMTI's ROE of -0.15%. Regarding short-term risk, EMBCV is more volatile compared to RMTI. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check RMTI's competition here
EMBCV vs CYTH Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, EMBCV is priced at $33.33, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas CYTH's P/E ratio is -0.80. In terms of profitability, EMBCV's ROE is -0.23%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, EMBCV is more volatile compared to CYTH. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check CYTH's competition here
EMBCV vs TXMD Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, TXMD has a market cap of 22.8M. Regarding current trading prices, EMBCV is priced at $33.33, while TXMD trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas TXMD's P/E ratio is 197.00. In terms of profitability, EMBCV's ROE is -0.23%, compared to TXMD's ROE of +0.01%. Regarding short-term risk, EMBCV is more volatile compared to TXMD. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check TXMD's competition here
EMBCV vs QNTM Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, QNTM has a market cap of 21.9M. Regarding current trading prices, EMBCV is priced at $33.33, while QNTM trades at $4.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas QNTM's P/E ratio is -0.63. In terms of profitability, EMBCV's ROE is -0.23%, compared to QNTM's ROE of -6.22%. Regarding short-term risk, EMBCV is less volatile compared to QNTM. This indicates potentially lower risk in terms of short-term price fluctuations for EMBCV.Check QNTM's competition here
EMBCV vs EVOK Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, EMBCV is priced at $33.33, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas EVOK's P/E ratio is -7.97. In terms of profitability, EMBCV's ROE is -0.23%, compared to EVOK's ROE of -1.01%. Regarding short-term risk, EMBCV is more volatile compared to EVOK. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check EVOK's competition here
EMBCV vs OPTH Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, OPTH has a market cap of 18.3M. Regarding current trading prices, EMBCV is priced at $33.33, while OPTH trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas OPTH's P/E ratio is -5.20. In terms of profitability, EMBCV's ROE is -0.23%, compared to OPTH's ROE of -0.57%. Regarding short-term risk, EMBCV is more volatile compared to OPTH. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check OPTH's competition here
EMBCV vs AYTU Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, AYTU has a market cap of 16.9M. Regarding current trading prices, EMBCV is priced at $33.33, while AYTU trades at $2.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas AYTU's P/E ratio is -0.45. In terms of profitability, EMBCV's ROE is -0.23%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, EMBCV is more volatile compared to AYTU. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check AYTU's competition here
EMBCV vs TLPH Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, TLPH has a market cap of 15.7M. Regarding current trading prices, EMBCV is priced at $33.33, while TLPH trades at $0.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas TLPH's P/E ratio is -2.73. In terms of profitability, EMBCV's ROE is -0.23%, compared to TLPH's ROE of -0.93%. Regarding short-term risk, EMBCV is more volatile compared to TLPH. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check TLPH's competition here
EMBCV vs ACRX Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, EMBCV is priced at $33.33, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas ACRX's P/E ratio is -0.31. In terms of profitability, EMBCV's ROE is -0.23%, compared to ACRX's ROE of -0.93%. Regarding short-term risk, EMBCV is more volatile compared to ACRX. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check ACRX's competition here
EMBCV vs COSM Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, COSM has a market cap of 13.4M. Regarding current trading prices, EMBCV is priced at $33.33, while COSM trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas COSM's P/E ratio is -0.37. In terms of profitability, EMBCV's ROE is -0.23%, compared to COSM's ROE of -0.96%. Regarding short-term risk, EMBCV is more volatile compared to COSM. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check COSM's competition here
EMBCV vs BFRI Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, BFRI has a market cap of 12.6M. Regarding current trading prices, EMBCV is priced at $33.33, while BFRI trades at $0.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas BFRI's P/E ratio is -1.01. In terms of profitability, EMBCV's ROE is -0.23%, compared to BFRI's ROE of -4.77%. Regarding short-term risk, EMBCV is more volatile compared to BFRI. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check BFRI's competition here
EMBCV vs AGRX Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, EMBCV is priced at $33.33, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas AGRX's P/E ratio is -0.89. In terms of profitability, EMBCV's ROE is -0.23%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, EMBCV is more volatile compared to AGRX. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check AGRX's competition here
EMBCV vs NLTX Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, EMBCV is priced at $33.33, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas NLTX's P/E ratio is -0.28. In terms of profitability, EMBCV's ROE is -0.23%, compared to NLTX's ROE of -0.38%. Regarding short-term risk, EMBCV is more volatile compared to NLTX. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check NLTX's competition here
EMBCV vs LCI Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, EMBCV is priced at $33.33, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas LCI's P/E ratio is -0.04. In terms of profitability, EMBCV's ROE is -0.23%, compared to LCI's ROE of +1.66%. Regarding short-term risk, EMBCV is more volatile compared to LCI. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check LCI's competition here
EMBCV vs YCBD Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, YCBD has a market cap of 7.3M. Regarding current trading prices, EMBCV is priced at $33.33, while YCBD trades at $0.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas YCBD's P/E ratio is 0.28. In terms of profitability, EMBCV's ROE is -0.23%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, EMBCV is more volatile compared to YCBD. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check YCBD's competition here
EMBCV vs BGXX Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, BGXX has a market cap of 7.3M. Regarding current trading prices, EMBCV is priced at $33.33, while BGXX trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas BGXX's P/E ratio is -0.76. In terms of profitability, EMBCV's ROE is -0.23%, compared to BGXX's ROE of -1.16%. Regarding short-term risk, EMBCV is more volatile compared to BGXX. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check BGXX's competition here
EMBCV vs ADMP Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, EMBCV is priced at $33.33, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas ADMP's P/E ratio is -0.08. In terms of profitability, EMBCV's ROE is -0.23%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, EMBCV is more volatile compared to ADMP. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check ADMP's competition here
EMBCV vs EGRX Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, EGRX has a market cap of 6.1M. Regarding current trading prices, EMBCV is priced at $33.33, while EGRX trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas EGRX's P/E ratio is 6.57. In terms of profitability, EMBCV's ROE is -0.23%, compared to EGRX's ROE of +0.17%. Regarding short-term risk, EMBCV is more volatile compared to EGRX. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check EGRX's competition here
EMBCV vs MNK Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, EMBCV is priced at $33.33, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas MNK's P/E ratio is -0.44. In terms of profitability, EMBCV's ROE is -0.23%, compared to MNK's ROE of -0.26%. Regarding short-term risk, EMBCV is less volatile compared to MNK. This indicates potentially lower risk in terms of short-term price fluctuations for EMBCV.Check MNK's competition here
EMBCV vs GELS Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, GELS has a market cap of 4.5M. Regarding current trading prices, EMBCV is priced at $33.33, while GELS trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas GELS's P/E ratio is -0.93. In terms of profitability, EMBCV's ROE is -0.23%, compared to GELS's ROE of -0.43%. Regarding short-term risk, EMBCV is more volatile compared to GELS. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check GELS's competition here
EMBCV vs FLGC Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, EMBCV is priced at $33.33, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas FLGC's P/E ratio is -0.19. In terms of profitability, EMBCV's ROE is -0.23%, compared to FLGC's ROE of -0.08%. Regarding short-term risk, EMBCV is less volatile compared to FLGC. This indicates potentially lower risk in terms of short-term price fluctuations for EMBCV.Check FLGC's competition here
EMBCV vs GHSI Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, GHSI has a market cap of 4.2M. Regarding current trading prices, EMBCV is priced at $33.33, while GHSI trades at $3.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas GHSI's P/E ratio is -0.79. In terms of profitability, EMBCV's ROE is -0.23%, compared to GHSI's ROE of +0.01%. Regarding short-term risk, EMBCV is more volatile compared to GHSI. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check GHSI's competition here
EMBCV vs RDHL Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, RDHL has a market cap of 3.1M. Regarding current trading prices, EMBCV is priced at $33.33, while RDHL trades at $0.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas RDHL's P/E ratio is N/A. In terms of profitability, EMBCV's ROE is -0.23%, compared to RDHL's ROE of +2.91%. Regarding short-term risk, EMBCV is more volatile compared to RDHL. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check RDHL's competition here
EMBCV vs CPHI Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, CPHI has a market cap of 2.8M. Regarding current trading prices, EMBCV is priced at $33.33, while CPHI trades at $0.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas CPHI's P/E ratio is -1.61. In terms of profitability, EMBCV's ROE is -0.23%, compared to CPHI's ROE of -0.19%. Regarding short-term risk, EMBCV is more volatile compared to CPHI. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check CPHI's competition here
EMBCV vs PLXP Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, EMBCV is priced at $33.33, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas PLXP's P/E ratio is -0.22. In terms of profitability, EMBCV's ROE is -0.23%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, EMBCV is less volatile compared to PLXP. This indicates potentially lower risk in terms of short-term price fluctuations for EMBCV.Check PLXP's competition here
EMBCV vs ATNX Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, EMBCV is priced at $33.33, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas ATNX's P/E ratio is -0.02. In terms of profitability, EMBCV's ROE is -0.23%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, EMBCV is more volatile compared to ATNX. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check ATNX's competition here
EMBCV vs SNOA Comparison June 2026
EMBCV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBCV stands at 1.9B. In comparison, SNOA has a market cap of 2.1M. Regarding current trading prices, EMBCV is priced at $33.33, while SNOA trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBCV currently has a P/E ratio of N/A, whereas SNOA's P/E ratio is -0.62. In terms of profitability, EMBCV's ROE is -0.23%, compared to SNOA's ROE of -0.86%. Regarding short-term risk, EMBCV is more volatile compared to SNOA. This indicates potentially higher risk in terms of short-term price fluctuations for EMBCV.Check SNOA's competition here